MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)

The Oncotype DX DCIS assay is covered only for women with a diagnosis of ductal carcinoma in situ (DCIS) who are planning breast-conserving surgery and are considering adjuvant radiation therapy. The provided excerpt restricts coverage to that specific clinical scenario; other uses or patient populations are not covered per the excerpt. Documentation and frequency limits are not specified here and require review of the full policy.

"Oncotype DX® DCIS assay is covered for women diagnosed with ductal carcinoma in situ (DCIS) who are planning breast-conserving surgery and are considering adjuvant radiation therapy."

Sign up to see full coverage criteria, indications, and limitations.